Financials data is unavailable for this security.
View more
Year on year Suven Pharmaceuticals Ltd 's revenues fell -21.56% from 13.40bn to 10.51bn. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from 4.11bn to 3.00bn, a -26.99% decrease.
| Gross margin | 61.42% |
|---|---|
| Net profit margin | 25.27% |
| Operating margin | 27.51% |
| Return on assets | 10.50% |
|---|---|
| Return on equity | 12.42% |
| Return on investment | 11.50% |
More ▼
Cash flow in INRView more
In 2024, cash reserves at Suven Pharmaceuticals Ltd fell by 175.72m. However, the company earned 3.58bn from its operations for a Cash Flow Margin of 34.10%. In addition the company used 3.62bn on investing activities and also paid 138.02m in financing cash flows.
| Cash flow per share | 11.91 |
|---|---|
| Price/Cash flow per share | 106.93 |
| Book value per share | 77.71 |
|---|---|
| Tangible book value per share | 67.05 |
More ▼
Balance sheet in INRView more
| Current ratio | 4.90 |
|---|---|
| Quick ratio | 4.00 |
| Total debt/total equity | 0.02 |
|---|---|
| Total debt/total capital | 0.0191 |
More ▼
Growth rates in INR
Year on year, growth in earnings per share excluding extraordinary items dropped -26.99%. Additionally, five year annualized earnings per share growth is in-line with the industry average relative to its peers.
| EPS growth(5 years) | 22.41 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -43.79 |
